Immune Complex Vasculitis

Etiology and Clinical Context

Immune complex vasculitis is a mechanism-based category rather than one disease. Circulating antigen–antibody complexes may form during infection, autoimmune disease, malignancy, or exposure to certain medications; local deposition and ineffective clearance produce small-vessel inflammation. Important patterns include IgA vasculitis, mixed cryoglobulinemic vasculitis, and hypocomplementemic urticarial vasculitis.

IgA vasculitis often follows a mucosal immune trigger and is characterized by IgA-dominant deposits affecting skin, gastrointestinal tract, joints, and sometimes kidneys. Cryoglobulinemic vasculitis can occur with hepatitis C, B-cell lymphoproliferative disease, or autoimmune conditions. Both need etiologic assessment, not just symptom suppression.

Epidemiology and Risk Profile

IgA vasculitis is more frequent in children, but renal involvement deserves particular attention in adults. Mixed cryoglobulinemic disease should be considered when the presentation occurs alongside hepatitis C, systemic autoimmunity, or a B-cell disorder. The dominant organ involvement also varies by subtype.

Pathophysiology

Immune complexes and complement

Immune complexes deposited in postcapillary venules and glomeruli activate complement and recruit neutrophils. Complement-derived C5a promotes chemotaxis and activation, while neutrophil enzymes and oxidants injure endothelium. The characteristic skin biopsy may show leukocytoclastic vasculitis, including neutrophilic debris and fibrinoid vessel-wall injury (Gelber et al., 2019).

Immunoglobulin and tissue-specific patterns

IgA vasculitis shows predominant IgA deposition by immunofluorescence. Cryoglobulins precipitate at cooler temperatures and can cause immune-complex occlusion and inflammation. Mixed cryoglobulinemic vasculitis is associated with hepatitis C, systemic autoimmunity, or B-cell disease, and disproportionately low C4 can be an important serologic clue (Moretti et al., 2024). In SLE-associated small-vessel disease, deposition can occur alongside broader systemic autoimmunity; the systemic phenotype and biopsy help identify the cause.

Renal injury

Glomerular immune deposits activate inflammatory pathways, impair capillary barrier function, and cause hematuria, proteinuria, reduced filtration, and sometimes rapidly progressive glomerulonephritis. A normal skin course cannot be assumed to predict a benign renal course. In adults with suspected IgA vasculitis and concerning kidney findings, biopsy can establish the glomerular diagnosis and help guide management (Kidney Disease: Improving Global Outcomes [KDIGO] IgAN and IgAV Work Group, 2025). The 2026 adult guideline supports biopsy when diagnosis is uncertain, kidney function declines rapidly, or urine protein/creatinine remains above 0.5 g/g for 2–4 weeks (Audemard-Verger et al., 2026).

Distinguishing Three Vascular Injury Patterns

Disorder	Pathogenic mechanism and vessel size	Characteristic clues
Immune-complex small-vessel vasculitis	Antigen–antibody deposits; complement/Fc-receptor activation; venules and sometimes glomeruli	Palpable purpura, arthralgia, hematuria/proteinuria; IgA or cryoglobulin pattern depends on subtype
Granulomatosis with polyangiitis (GPA)	Often ANCA-associated, pauci-immune neutrophil-mediated small-vessel injury	ENT/pulmonary disease, possible necrotizing glomerulonephritis; biopsy/ANCA in context
Polyarteritis nodosa (PAN)	Necrotizing inflammation of medium muscular arteries, not primarily glomerular immune-complex deposition	Organ ischemia, mononeuritis multiplex, abdominal pain, renal-artery hypertension; glomerulonephritis is not typical

Immune-complex injury can follow persistent antigen exposure, with vascular deposition and activation of complement and Fc receptors causing leukocytoclastic vessel damage. In contrast, ANCAs in GPA activate neutrophils without prominent immunoglobulin deposition in classic pauci-immune lesions. PAN primarily affects medium arteries, creating ischemia and renovascular hypertension rather than typical glomerular immune-complex nephritis; the pulmonary circulation is usually spared. Hepatitis B is an established but now less common associated trigger (Chung, Gorelik, et al., 2021).

Palpable purpura accompanied by active urinary sediment raises concern for small-vessel disease. Hypertension with visceral ischemia or neuropathy can suggest medium-vessel involvement. A pulmonary–renal syndrome requires urgent assessment for ANCA-associated vasculitis and other serious causes.

Immune-Complex Subtypes and Organ Distribution

The pattern of immune deposition identifies a mechanism, but the clinical phenotype directs the search for its cause. Management may involve treating an underlying infection or B-cell process, providing supportive care, or controlling organ-threatening inflammation (KDIGO IgAN and IgAV Work Group, 2025).

Phenotype	Initiating mechanism	Most important organ implications
IgA vasculitis	IgA1-dominant immune deposits, frequently after mucosal immune stimulation; small-vessel leukocytoclasia and sometimes glomerular mesangial injury	Dependent palpable purpura, joint symptoms, abdominal pain or GI bleeding, and possible nephritis
Mixed cryoglobulinemic vasculitis	Immune complexes containing cryoprecipitable immunoglobulins, often linked to chronic hepatitis C, autoimmune disease or B-cell disorders	Purpura, peripheral neuropathy, glomerulonephritis; low C4 may be prominent
Hypocomplementemic urticarial vasculitis	Complement-activating immune complexes, sometimes associated with anti-C1q antibodies	Painful or burning urticarial lesions lasting more than 24 hours with residual discoloration; possible renal, lung or joint involvement
Drug- or infection-associated immune-complex disease	Persistent or newly generated antigens produce antibody complexes and vessel-wall deposition	Variable skin, kidney and systemic effects; the trigger must be identified before immunosuppression

The distinction becomes particularly important when pulmonary, renal, or neurologic findings do not fit the suspected immune-complex subtype. Pauci-immune biopsy findings or evidence of medium-artery ischemia should redirect the workup toward ANCA-associated vasculitis or PAN (Chung, Gorelik, et al., 2021; Chung, Langford, et al., 2021).

Clinical Manifestations

Palpable nonblanching purpura, often on dependent lower extremities, reflects inflamed small dermal vessels with erythrocyte extravasation. IgA vasculitis may also cause abdominal pain, gastrointestinal bleeding, arthralgia or arthritis, and nephritis. In cryoglobulinemic disease, purpura, arthralgia, weakness, peripheral neuropathy, and renal abnormalities may coexist.

Urticarial vasculitis lesions frequently persist beyond 24 hours and may leave bruising or residual hyperpigmentation, unlike the transient wheals of urticaria (Gu & Jorizzo, 2021). Fever, weight loss, neuropathy, pulmonary findings, or progressive renal dysfunction suggest systemic rather than skin-limited disease.

Diagnostic Evaluation

Begin with CBC, inflammatory markers, metabolic profile, renal function, blood pressure, urinalysis, and urine protein quantification. Complement C3/C4 and directed testing for hepatitis B/C, autoimmune disease, serum cryoglobulins, and immunoglobulins depend on the phenotype. Cryoglobulin sampling requires specialized temperature-controlled handling; improper collection can cause false-negative results.

Biopsy a fresh, active lesion when feasible. Routine histology evaluates leukocytoclastic injury; direct immunofluorescence helps characterize immunoglobulin/complement deposition. Negative or nonspecific skin immunofluorescence does not exclude a vasculitic syndrome, particularly in older lesions.

ANCA testing is useful when the differential includes ANCA-associated disease, but a positive ANCA is not proof of immune-complex vasculitis. ANCA-associated glomerulonephritis is classically pauci-immune, in contrast to the immunoglobulin-rich deposits expected in immune-complex glomerulonephritis.

Expected Findings and Diagnostic Interpretation

Investigation	What it reveals	How to use the result
CBC and platelet count	Inflammatory anemia is possible; thrombocytopenia suggests an alternate cause of purpura	A nonblanching rash alone cannot distinguish vasculitis from low platelets or coagulopathy
Urinalysis, urine microscopy and protein quantification	Dysmorphic RBCs, casts and proteinuria suggest glomerular injury	Serial urine findings, blood pressure and creatinine assess nephritis risk; skin findings can resolve first
Complement C3/C4 and cryoglobulins	Markedly low C4 supports some mixed cryoglobulinemic phenotypes; normal levels occur in IgA vasculitis	Do not use normal serum complement to exclude tissue-localized immune complexes
Fresh skin biopsy with separate direct immunofluorescence specimen	Leukocytoclastic vessel injury with IgA, C3 or other immune deposits may identify the subtype	Biopsy timing, depth and lesion selection affect sensitivity; older lesions can lose detectable deposits
Kidney biopsy when indicated	IgA-dominant glomerular deposits or other immune-complex patterns; grades activity/chronic damage	Helps determine renal prognosis and immunomodulatory strategy rather than relying on serum markers

If the presentation suggests hepatitis-associated cryoglobulinemia, test hepatitis serologies and confirmatory virologic assays as appropriate. Cryoglobulin collection and processing require strict warm handling until serum separation. Suspected PAN may instead need angiographic assessment of medium-vessel abnormalities or a deep biopsy of involved tissue (Chung, Gorelik, et al., 2021).

Differential Diagnosis

A palpable purpuric eruption should prompt a mechanism-based differential. Thrombocytopenia or coagulopathy can cause nonblanching lesions without inflammatory vessel-wall injury. Infective endocarditis and other infections can produce immune-complex manifestations or embolic lesions, making infection evaluation essential before assuming primary autoimmunity. Leukocytoclastic biopsy findings occur in several etiologies and do not independently establish IgA vasculitis. Consider ANCA-associated vasculitis with pulmonary–renal involvement, PAN with visceral ischemia or mononeuritis multiplex, and antiphospholipid or other occlusive disease when the phenotype is predominantly thrombotic.

Diagnostic Limitations and Reassessment

A negative direct immunofluorescence result from an older lesion does not reliably exclude immune-complex vasculitis. Serum complement may be normal despite active IgA vasculitis; circulating IgA elevation is nonspecific. Continue monitoring urinalysis, urine protein, creatinine, and blood pressure after the eruption subsides because nephritis may appear later. The 2026 adult guideline proposes reassessment every 1–3 months during the first year and every 6–12 months thereafter, tailored to severity and relapse risk (Audemard-Verger et al., 2026). Rapid kidney function loss, pulmonary hemorrhage, or gastrointestinal ischemia requires urgent specialist evaluation.

Practical evaluation sequence

• First establish hemodynamic and organ stability, including kidney, respiratory, neurologic and abdominal findings.
• Distinguish platelet/coagulation causes and embolic or infectious processes from true vessel inflammation.
• Obtain tissue from an appropriate active lesion and investigate the antigenic trigger and immune-complex subtype.
• Reassess organ function over time rather than using rash improvement as a marker of systemic recovery.

Management and Mechanistic Rationale

Treatment depends on cause, involved organs, and severity. Remove an implicated medication or treat a triggering infection when appropriate. Skin-limited disease may require supportive management, while organ-threatening disease can require specialist-directed glucocorticoids and immunomodulatory treatment. In hepatitis C–associated cryoglobulinemia, addressing viral replication is central to controlling the antigenic trigger.

Renal supportive care often includes blood-pressure and proteinuria management. KDIGO 2025 advises against systemic glucocorticoids solely to prevent nephritis in patients with isolated extrarenal IgA vasculitis; established renal disease is a different scenario requiring severity-specific evaluation. Immunosuppression is not reflexively indicated for every case of palpable purpura.

Complications and Red Flags

Monitor for active urinary sediment, worsening kidney function, nephritic or nephrotic syndromes, severe gastrointestinal bleeding or ischemia, pulmonary hemorrhage, and new peripheral neuropathy. Severe abdominal pain, rapidly rising creatinine, oliguria, or respiratory symptoms require urgent reassessment.

Do not mistake thrombocytopenic purpura or embolic/occlusive disease for palpable vasculitic purpura without assessing platelet count and morphology.

Clinical Reasoning Priorities

Reason from vascular pattern → immunoglobulin/complement mechanism → organ distribution → trigger → severity. A skin biopsy establishes a pattern, not always the cause. Pair tissue evidence with infection, autoimmune, and malignancy evaluation when appropriate.

Complement consumption is informative but not universal. Low C4 is often prominent in cryoglobulinemia; IgA vasculitis may occur with normal systemic complement measurements. Organ assessment should never be deferred until complement testing returns.

Applied Clinical Reasoning

Clinical question: A patient develops palpable lower-leg purpura after a respiratory illness, ankle pain, and microscopic hematuria. Platelets are normal. Is this only a dermatologic process?

Reasoning: Palpable purpura with hematuria may be the first indication of systemic small-vessel disease rather than an isolated skin eruption. Assess blood pressure, kidney function, urine sediment, and proteinuria while investigating IgA vasculitis and other immune-complex causes. Biopsy decisions and treatment urgency depend largely on the severity and progression of organ involvement.

High-Yield Distinctions

Finding or scenario	Mechanistic interpretation	Clinical implication
Purpura + abdominal pain + hematuria	IgA-dominant small-vessel/glomerular injury	Consider IgA vasculitis and assess renal involvement
Purpura + neuropathy + low C4	Mixed cryoglobulinemic immune complexes	Evaluate hepatitis C, autoimmune disease, and B-cell disorders
Rapidly progressive kidney injury with little immune deposition	Pauci-immune necrotizing glomerulonephritis	Evaluate ANCA-associated vasculitis rather than assuming immune-complex disease

Related YourDNP Guides

• Back to Pathophysiology
• Immunology Foundations
• Systemic Lupus Erythematosus
• Musculoskeletal and Rheumatic Foundations

---

---

References

Audemard-Verger, A., Pillebout, E., Baier, E., Bajema, I. M., Barratt, J., Bertsias, G., Bruchfeld, A., Castañeda, S., Cid, M. C., Coppo, R., Direskeneli, H., Errichiello, C., Floege, J., González-Gay, M. A., Gül, A., Hankard, A., Hočevar, A., Jachiet, M., Jelusic, M., . . . the collaborators of the EUGAVAS Study Group on behalf of the European Vasculitis Society (EUVAS). (2026). Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis. Nature Reviews Rheumatology, 22, 643–662. https://doi.org/10.1038/s41584-026-01420-3

Chung, S. A., Gorelik, M., Langford, C. A., Maz, M., Abril, A., Guyatt, G., Archer, A. M., Conn, D. L., Full, K. A., Grayson, P. C., Ibarra, M. F., Imundo, L. F., Kim, S., Merkel, P. A., Rhee, R. L., Seo, P., Stone, J. H., Sule, S., Sundel, R. P., . . . Mustafa, R. A. (2021). 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Care & Research, 73(8), 1061–1070. https://doi.org/10.1002/acr.24633

Chung, S. A., Langford, C. A., Maz, M., Abril, A., Gorelik, M., Guyatt, G., Archer, A. M., Conn, D. L., Full, K. A., Grayson, P. C., Ibarra, M. F., Imundo, L. F., Kim, S., Merkel, P. A., Rhee, R. L., Seo, P., Stone, J. H., Sule, S., Sundel, R. P., . . . Mustafa, R. A. (2021). 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care & Research, 73(8), 1088–1105. https://doi.org/10.1002/acr.24634

Gelber, A. C., Levine, S. M., & Darrah, E. (2019). Inflammatory rheumatic diseases. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed., Chapter 24). McGraw-Hill Education. AccessMedicine

Gu, S. L., & Jorizzo, J. L. (2021). Urticarial vasculitis. International Journal of Women’s Dermatology, 7(3), 290–297. https://doi.org/10.1016/j.ijwd.2021.01.021

Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. (2025). KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy and immunoglobulin A vasculitis. Kidney International, 108(4S), S1–S71. https://doi.org/10.1016/j.kint.2025.04.004

Moretti, M., Ferro, F., Baldini, C., Mosca, M., & Talarico, R. (2024). Cryoglobulinemic vasculitis: A 2023 update. Current Opinion in Rheumatology, 36(1), 27–34. https://doi.org/10.1097/BOR.0000000000000989